Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
3 Biotech Stocks You Should Know About
02:35pm, Wednesday, 17'th Jul 2024
In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?
01:00pm, Tuesday, 16'th Jul 2024
Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
01:06pm, Monday, 08'th Jul 2024
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
08:00am, Saturday, 06'th Jul 2024
Sarepta Therapeutics just received expanded labeling for one of its therapies. But the therapy has not performed as well as expected in clinical trials.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
06:35am, Thursday, 04'th Jul 2024
Previously, Sarepta's gene therapy treatment Elevidys was approved for only a limited number of Duchenne muscular dystrophy patients. Regulators, however, have expanded that range, and it can now be u
Best Momentum Stocks to Buy for July 3rd
11:00am, Wednesday, 03'rd Jul 2024
SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024.
1 Soaring Growth Stock to Buy and Hold for 10 Years
10:05am, Wednesday, 03'rd Jul 2024
Sarepta Therapeutics' most important medicine now looks even more promising. The biotech's financial results are improving substantially.
New Strong Buy Stocks for July 3rd
07:50am, Wednesday, 03'rd Jul 2024
MONDY, MWA, SRPT, ASYS and CLCO have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2024.
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
10:06am, Wednesday, 26'th Jun 2024
Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
Will Elevidys Approval Make Sarepta Stock An Acquisition Target?
09:00am, Tuesday, 25'th Jun 2024
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Frid
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
04:50am, Monday, 24'th Jun 2024
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
06:47am, Saturday, 22'nd Jun 2024
Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary
Sarepta CEO on what's next after expanded muscular dystrophy drug approval
07:05pm, Friday, 21'st Jun 2024
Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.
TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval
05:45pm, Friday, 21'st Jun 2024
Ritu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day i
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
